Fenwick Represents Maze Therapeutics in $150M Private Placement

Fenwick represented Maze Therapeutics, a clinical-stage biopharmaceutical company, in its $150 million private placement of common stock and pre-funded warrants. Additional information can be obtained here.

Maze is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases.

The Fenwick transaction team was led by corporate partners Amanda Rose, Chelsea Anderson and Effie Toshav and included associates Marianna Zabkowski, Sarah Marshall and Sydney Everett.